ClinicalTrials.gg
RecruitingNCT05669183RECOVERYUpdated Apr 4, 2024

Hemodynamic Comparison of Peripheral and Central VA ECMO.

An observational study in Shock, Cardiogenic, Cardiac Arrest and Extracorporeal Circulation; Complications, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
136
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Shock, Cardiogenic with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Shock, Cardiogenic · China.

Started
2023
with 2 others
Observational
6 of 20
6 open now
Primary completion
2024-10
later than 2 of 17 live
Registered
10th of 20
by date
Lead sponsor
1 of 20
First Affiliated Hospital Xi'an Jiaotong University

Among the 20 studies in Shock, Cardiogenic with a site in China, this one is one of 3 that started in 2023, is one of 6 observational ones, reaches primary completion later than 2 of the 17 other live ones, and was the 10th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

18 of the 20 studies in Shock, Cardiogenic with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Shock, Cardiogenic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to monitor hemodynamic differences between central veno-arterial extracorporeal membrane oxygenation (VA ECMO) and peripheral VA ECMO. The main question it aims to answer is:

  • Efficacy of the different cannulation strategies for the establishment of for VA-ECMO circulation on hemodynamics and organ perfusion.

Participants require VA ECMO support, will be divided into two groups in an intention-to-treat analysis: central artery cannulation and peripheral artery cannulation.

Researchers will analyze different cannulation strategies for VA-ECMO and identify potential advantages and disadvantages for two groups of VA-ECMO.

03

Conditions studied

  • Shock, Cardiogenic
  • Cardiac Arrest
  • Extracorporeal Circulation; Complications
  • Hemodynamics Instability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants require VA ECMO support for cardiogenic shock or cardiac arrest.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18 years
  • Participants with cardiogenic shock
  • Obtaining from participants or their affiliated beneficiaries

Exclusion criteria

Exclusion Criteria:

  • Irreversible heart failure
  • to anticoagulation therapy
  • Uncontrolled bleeding
  • Irreversible neurological pathology
  • Participants limited to extracorporeal cardiopulmonary resuscitation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
136 participants (estimated)
Patient registry
No

Groups and cohorts

  • Peripheral VA ECMO

    Femoral artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)

    Procedure: Veno-arterial extracorporeal membrane oxygenation

  • Central VA ECMO

    Axillary artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)

    Procedure: Veno-arterial extracorporeal membrane oxygenation

Interventions

  • ProcedureVeno-arterial extracorporeal membrane oxygenation

    Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.

06

What researchers measure

Primary outcomes

  1. Oxygen saturation-no. (%)

    Blood gas analysis

    Time frame: Through VA ECMO support completion, an average of 1 week

  2. Left ventricular end-diastolic volume (ml)

    echocardiography

    Time frame: Through VA ECMO support completion, an average of 1 week

  3. Left ventricular End-systolic volume (ml)

    echocardiography

    Time frame: Through VA ECMO support completion, an average of 1 week

  4. Stroke volume (ml)

    echocardiography

    Time frame: Through VA ECMO support completion, an average of 1 week

  5. Mitral valve area(cm2)

    echocardiography

    Time frame: Through VA ECMO support completion, an average of 1 week

Secondary outcomes

  1. Rate of successful weaning from VA ECMO

    Weaning success is defined as survival after complete removal of the extracorporeal circuit without requirement for further mechanical support or heart transplant.

    Time frame: Through study completion, up to 2 years

  2. VA ECMO duration

    Length of VA ECMO support

    Time frame: Through VA ECMO support, an average of 1 week

  3. Cannulation-related complications

    Cannulation-related complications include bleeding, limb ischemia, revision of cannulation site, wound complications. Limb ischemia is defined as ischemia requiring any surgical procedure, including revision of the arterial/distal perfusion cannula, fasciotomy for compartment syndrome, gangrene, or amputation. Wound complication is defined as infection or requirement of an additional surgical intervention, such as arterial repair, washout with or without vacuum-assisted closure, and muscle flap closure.

    Time frame: Through study completion, up to 2 years

  4. Duration of ICU stay

    Intensive care unit length of stay

    Time frame: Through study completion, up to 2 years

  5. Duration of hospital stay

    Length of hospital stay

    Time frame: Through study completion, up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Oct 2024, 14 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 14 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2022
First posted
Dec 30, 2022
StartActual
Aug 12, 2023
Primary completionEst.
Oct 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669183
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Aug 12, 2023
Primary completion
Oct 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 4, 2024

Study contacts

Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-18991232621
Fengwei Guo
Contact
guofengwei@xjtu.edu.cn
0086-13991259800
Yang Yan
study director · First Affiliated Hospital of Xian Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion